CA Hull Investments boosts stake in Sequent Scientific post-merger

Sequent Scientific Limited announced that its equity share capital and voting rights have changed significantly following a composite scheme of amalgamation approved by the National Company Law Tribunal, Hyderabad bench, on November 18, 2025. As a result, CA Hull Investments, along with its Person Acting in Concert (PAC), CA Harbor Investments, have substantially increased their stake in Sequent.

Pursuant to the scheme, Sequent allotted 13,61,60,231 equity shares of INR 2/- each to CA Hull Investments, representing 31.2% of the total paid-up share capital. Prior to this, CA Hull Investments held 52.33% of the share capital, which has now been diluted to 30.2% post-merger, while CA Harbor Investments' shareholding increased from 30.20% to 61.4% of Sequent’s total share capital.

The allotment was made to shareholders of Viyash Life Sciences Private Limited at an exchange ratio of 56 fully paid-up equity shares of Sequent (INR 2/- each) for every 100 fully paid-up equity shares of Viyash (INR 10/- each). This acquisition is exempt from open offer obligations under Regulation 10(1)(d)(ii) of the SEBI Takeover Regulations, 2011, as it resulted from a court-approved scheme of arrangement.